Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 16/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.46 |
| ▸ | LGMN | Q99538 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 2/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21874279 | 0.88 | EP300 (0.48) | EP300CREBBPLGMN | |
| SCHEMBL21874104 | 0.80 | TAS1R3 (0.46) | CFD | |
| SCHEMBL23485121 | 0.72 | CYP1A2 (0.48) | CFD | |
| SCHEMBL29510632 | 0.72 | CYP1A2 (0.48) | CFD | |
| SCHEMBL21964998 | 0.72 | EP300 (0.41) | EP300CREBBPCFD | |
| SCHEMBL21874087 | 0.71 | EP300 (0.66) | EP300CREBBP | |
| SCHEMBL21874316 | 0.71 | EP300 (0.51) | EP300CREBBP | |
| SCHEMBL21874299 | 0.69 | EP300 (0.57) | EP300CREBBP | |
| SCHEMBL21874225 | 0.68 | EP300 (1.00) | EP300CREBBP | |
| SCHEMBL23485568 | 0.68 | EP300 (1.00) | EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | EP300 1/4885CREBBP 2/4885LGMN 4680/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | EP300 1/4885CREBBP 2/4885LGMN 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.